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Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 
30% of breast cancer patients with poor prognosis. In addition, microRNAs are small 
non-coding RNA that have been linked to many cancers. Here we investigate which 
miRNAs are differentially regulated by HER2 overexpression. Using quantitative 
reverse-transcription prolymerase chain reaction (QRT-PCR) and matching it with the 
clinical data acquired from Dvinge, we find five candidate miRNAs. When comparing 
the miRNAs’ effect on patient survival, only three miRNAs stand as good predictors of 
patient survival outcome. These miRNAs are miR-146a-5p, miR-181d, and miR-195-5p. 
When miR-146a-5p is up-regulated, which is the case in HER2 positive patients, survival 
of patients drop significantly. In addition, miR-181d and miR-195-5p are down-regulated 
in HER2. With these two miRNA having low levels, the patient survival drops. Therefore, 
this data indicates that miR-146a-5p, miR-181d, and miR-195-5p are potential markers 
for patient survival and that their expression leves are highly associated with HER2 
overexpression. 
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 For many decades, cancer has been rigorously analyzed in many laboratories and 
population-based researched throughout the world. Due to the dedication of many 
scientists, a plethora of information is found where we can peer into cancer. However, 
even though scientists have been hard at work in understanding cancer, no complete cure 
has been found for the disease. This leaves us with the fact that we have not understood a 
lot about cancer. In order to realize what is yet unknown, we must talk about what we 
already know about cancer. 
 Cancer occurs in patients due to a multitude of factors that changes the behaviors 
of cells. There are six hallmarks of cancer that describes what a cancer cell needs to be 
able to acquire in order to be cancerous. These hallmarks are: evading growth suppressors, 
activating invasion and metastasis, enabling replicative immortality, inducing angiogensis, 
resisting cell death, and sustaining proliferative signaling (Hanahan & Weinberg 2011). 
Though diet is considered a major contributor to the formation of cancer cells (Willett 
2000), the fundamental change in this formation is a genetic change. This change is a 
mutation that produces a dominant oncogene that promotes tumor formation and 
recessive tumor suppressor genes that keep tumors at bay (Hanahan & Weinberg 2000). 
Oncogenes is a term used to described genes that, wen over expressed, 
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promote tumor formation, whereas tumor-suppressor genes are genes that inhibit tumor 
formation and are generally down regulated in tumors. With enough accumulation of 
mutation to oncogenes and tumor suppressor genes, ay cell can turn into a cancer cell. 
These cancer cells would then have the ability to proliferate indefinitely and generate 
tumors (Lobo et al 2007). Therefore, it is apparent tha  the scientific community has a 
large understanding and has progressed in the molecular mechanism of the cellular 
machinery in tumorigenesis (Reya et al 2001). However, due to the immensely complex 
nature that is the molecular and biochemical mechanism and pathways that control cell 
behavior, there is a mass sum of information that has yet to be uncovered to better 
understand and treat cancer. 
 
1.2: Breast Cancer: 
 Because of the complex mechanisms that control cell behaviors, cancer can 
manifest in different types. Among these types are solid tumors that are of epithelial 
origin. These epithelial tumors account for a signif cantly large cancer burden derived 
from many tissues such as breast, colon, ovary, lung, prostate, pancreas, and brain which 
constitute 80% of cancers (Visvader & Lindeman 2008). In the United States, breast 
cancer is the number one most common cancer in women and it is a leading cause of 
death among these women second only to lung cancer (Centers for Disease Control and 
Prevention [CDC], 2013). Breast cancer is the cause of more than 40,000 cancer-related 
deaths recorded annually in the U.S. among women (Klonisch et al 2008). In order to 
understand different types of breast cancer, we must briefly explore the morphology of 
the breast and the molecules that affect them. The breast is made up of fat and imbedded 
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in this fat is the mammary gland. The mammary gland is formed of branched ducts 
terminating in lobular and alveolar units (Klonisch et al 2008). Different cell lineages 
occupy different parts of the mammary gland. The myoepithelial cells line the basement 
layer of both the ducts and alveoli. The ducts and the alveoli are formed by the ductal 
epithelial cells and the alveolar epithelial cells re pectively, with the alveolar epithelial 
cells having the ability to produce milk (Klonisch et al 2008). The breast cells are highly 
influenced by different signals from the body, such as growth factors and the hormones 
estrogen and progesterone. On their surface, the cells contain receptors for these signals 
that they keep at a controlled quantity. Overexpression of surface receptors can cause 
alternations in the signaling cascade downstream of the receptor. These alterations can 
cause a shift in cell proliferation rate and intercellular change that can cause genomic 
instability and the transformation of normal cells into cancerous cells (Hanahan & 
Weinberg 2000). 
 Furthermore, the overexpression of the surface recptors is caused by mutations in 
the gene expression mainly. Therefore, based on gene microarray, it has been deduced 
that there are five subtypes of breast cancer depending on their gene expression pattern. 
These subtypes are: luminal A, luminal B, basal-like, normal-like, and human epidermal 
growth factor receptor 2 (HER2) positive tumors (Perou et al 2000). Luminal A and 
luminal B breast tumors are estrogen receptor positive (ER+), which means they 
overexpress the estrogen receptor. However, the diff rence between luminal A and 
luminal B tumors is dependent on the tumor grade. Tumor grades are scored from three to 
nine based on the differentiation of the tumor cells. The differentiation ranges from well-
differentiated to poorly differentiated tumors with the former having the best prognosis 
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and the latter having the worst. Luminal A is of the well-differentiated grade and luminal 
B is among the poorly differentiated grade. Among all types of breast cancers, luminal A 
has the best prognosis for the patient, along with the normal-like tumors (Metzger Filho 
et al 2011). Basal-like tumors are tumors that are negative for ER, progesterone receptor 
(PR), and HER2. The basal-like tumors generally are found in 10%-15% of all tumors 
and carry with them bad prognoses for the patient (Perou 2011). In addition, some of the 
tumors that are classified under one subtype or the ot r can carry genetic similarities 
with tumors that are classified under a different subtype. For example, basal-like tumors 
can be enriched with HER2 and yet still be under th basal-like tumor type (Perou 2011). 
 HER2 is one of those receptors, when overly expressed, can cause genomic 
instability which can transform normal cells into can er cells in the breast and thus is 
considered an oncogene. The HER2 gene is located in the long arm of chromosome 17 
(17q12). HER2 is named so because it shows high resemblance to the structure of the 
human epidermal growth factor receptor (HER1). Furthermore, HER2 is also known by 
other names for different reasons. It can also be call d ErbB-2 because it shows similarity 
to the avian erythroblastosis oncogene B (ErbB) (Coussens et al 1985).  
 HER2 is a ligand-independent receptor tyrosine kinase that can amplify the 
signaling pathway from other growth factors (Citri & Yarden 2006). The extracellular 
domain of HER2 stays in a constitutively active confirmation (Yan et al 2014). HER2 can 
homodimerize and heterodimerize, and with the constant active confirmation, HER2 
becomes the preferred dimerizing partner of HER1, HER3, and HER4. The dimerization 
causes an autophosphorylation (attachment of a phosphate molecule) to the amino acid 
tyrosine in the HER2 receptor which initiates the signaling cascade (Olayioye 2001). 
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 In normal cells, HER2 expression is responsible for cell survival, proliferation, 
differentiation, migration and apoptosis (Olayioye 2001, Roy & Perez 2009). For that 
reason, HER2 expression is tightly regulated. In approximately 30% of breast cancer, 
HER2 is overexpressed, and this type of breast cancer is called a HER2-positive breast 
cancer (Korkaya et al 2008). This overexpression causes an increase in the homo and 
heterodimerization which promotes tumorogenic signal ng cascade (Yan et al 2014). 
HER2-positive breast cancer cases tend to have very low survival rates due to the over-
expression of HER2 and its effect leading to tumorigenesis, increased invasiveness, and 
metastasis (Sorlie et al 2001). Some of these HER2 signaling cascades invovles pathways 
that include the phosphoinositide 3-kinase (PI3K/Akt) pathway, the Ras pathway, and the 
NFκB pathway (Feldman et al 2007, Merkhofer et al 2010) (Figure 1.1) 
 HER2-positive breast cancer treatments include using antibodies and 
chemotherapy. Among the antibodies, trastuzumab is well known as having a very 
significant positive effect on HER2-positive breast cancer patients. Trastuzumab results 
in an overall response rate of 20%-35% in previously ntreated HER2-positive breast 
cancer, resulting in progression free survival and overall survival. These results are 
intensified with the combination of chemotherapy along with the trastuzumab treatment 
(Roy & Perez 2009). However, despite the promising uccess of trastuzumab, most 
HER2-positive breast cancer patients do not respond t  trastuzumab regardless of 
whether it is single-agent or combined with chemotherapy. In addition, for those patients 
who do respond to trastuzumab, a big majority end up eveloping a resistance to the 
antibody (Roy & Perez 2009). Understanding the pathw y will help in locating better 
targets for treatment or even better markers for an early diagnosis. 
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Figure 1.1: HER2 pathway: 
Depiction of the HER2 pathway affecting three major pathways according to literature. 
Right branch is PI3K/Akt pathway leading to mTOR. Middle branch is the Ras and Raf 
eventually leading to the MEK and ERK pathway. Left branch is the pathway eventually 
leading to the NFκB pathway. 
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1.3: microRNA: 
 MicroRNAs (miRNA) are small non-coding regulatory RNA that are, on average, 
21 nucleotides long that regulate the expression of proteins post-transcriptionally. There 
are over a thousand miRNA in human cells that are all produced first in the nucleus as 
primary miRNA (pri-miRNA) in the shape of a stem-loop (Lee et al 2002). The miRNAs 
are then cleaved by an RNase III enzyme called Drosha, which produces a ~70 nucleotide 
product called pre-micro RNA (pre-miRNA) (Lee et al 2003). RNase III enzymes are 
proteins that are dsRNA-specific endonucleases that produce staggered cuts on both sides 
of the RNA helix (Filippov et al 2000). Once pre-miRNA is produced, it is shuttled out of 
the nucleus and into the cytoplasm to be processed by another RNase III enzyme called 
Dicer. Dicer cleaves the loop from the pre-miRNA producing a ~21 nucleotide double 
stranded miRNA (Lee et al 2002). The desirable strand of the double stranded miRNA is 
separated and is placed in the RNA-induced silencing omplex (RISC) while the 
undesired strand – called the passenger strand – is egraded (Okamura et al 2008, Rana 
2007). RISC is a ribonucleoprotein complex which contains RNA and proteins and can 
also be known as miRNP (Schwarz & Zamore 2002) (Figure 1.2). 
 The proteins from the Argonaute (Ago) protein family are essential for the 
function of RISC. The Ago proteins contain binding domains that help bind and orient 
the mature miRNA to interact with the targeted messenger RNA (mRNA). RISC silences 
mRNA translation by either inhibiting translation or degrading the mRNA. When there is 
complete complementarity between the miRNA in RISC and the mRNA, the mRNA gets 
degraded. However, when there is only partial comple entarity between the miRNA in 
RISC and mRNA, there is only silencing of the mRNA and inhibition of translation. The 
8 
silencing and degradation occurs in many different ways, including binding to the 3 
prime untranslated region (3’-UTR) of the mRNA and/or decapping the 5’ cap of the 
mRNA (Filipowicz et al 2008, Schwarz & Zamore 2002). Therefore, because miRNA are 
regulatory RNA, they are generally tightly regulated. 
 When regulation of miRNAs becomes faulty, alterations of miRNA expression 
can occur and would be associated with many malignant human ailments such as cancer 
(Bartel 2009). miRNAs’ DNA sequences have been report d in many deletion and over-
expression sites of other genes. This means that they may be expressed or repressed along 
with the expression or repression of the DNA where they were located (Calin et al 2004). 
Likewise, miRNAs have also been suggested to act as tumor initiation miRNAs 
(oncomirs) or tumor suppressor miRNAs depending on their targeted genes (Esquela-
Kerscher & Slack 2006). For example, if a miRNA targets HER2, then it is considered a 
tumor suppressor miRNA because HER2 is an oncogene and would generally be down-
regulated or suppressed in cancer. On the other hand, miRNAs that target p53, a well-
known tumor suppressor gene, are considered oncomirs, and their expression is generally 
up-regulated in cancer. An example of a tumor suppressor miRNA is miR-195-5p that is 
normally down-regulated and has been observed to show uppressive capabilities in 
hepatocellular carcinomas (Wang et al 2013). In addition, miRNAs have also been 
proposed to be used as biomarkers for cancers as a w y of identifying the types of 
cancers that are involved, such as miR-146a-5p as a biomarker for colorectal tumor 
localization (Iorio et al 2005, Omrane et al 2014). 
 Though many miRNAs have been studied extensively in many cancers, miRNA 
regulations in breast cancers – specifically HER2-positive breast cancers – were not 
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researched as extensively. Consequently, there remains a whole host of miRNAs and 
their pathways that can be explored to further our understanding of the molecular 
mechanism by which HER2-positive breast cancer functio s. Since HER2 regulates and 
increases tumor survivability, invasiveness, and metastasis, disrupting the signal cascade 
that results from the regulation of miRNA may aid in slowing down tumor progression 
and lead to a better prognosis for patients. 
 
1.4: Clinical implications: 
 HER2 positive breast cancer patients are ~30% of the total breast cancer patient 
population and generally have extremely low prognosis (Korkaya et al 2008). Although 
some drugs have been established to have some positive effect on HER2 positive cancer, 
such as trastuzumab, the number of patients that respond to the treatment are low, and the 
drug activity is diminished after a while (Roy & Perez 2009). Therefore, it is important to 
better understand the complex HER2 pathway to develop better treatments and drugs that 
have more specific and effective targets. 
Part of understanding the HER2 positive cancer is to understand how miRNAs are 
involved in the HER2 pathway. It is known that miRNAs are involved in many pathways 
in cancer and serve as biomarkers for cancer identification. However, miRNAs’ 
involvement in the HER2 pathway has scarcely been studied, and there remain many 
avenues to discover regarding HER2 and miRNAs. Therefore, we propose that the HER2 
overexpression will lead to differential regulation f a number of miRNAs that can help 
HER2 maintain the cancer’s tumorigenicity. 
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Figure 1.2: miRNA processing pathway: 
The miRNA processing pathway starts off in the nucle s. Drosha and Dicer are two 
RNase III enzymes for processing RNA. Pri-miRNA is the primary-miRNA. Pre-miRNA 




Materials and Methods 
 
2.1: Cell Culture: 
 MCF10A-Vector and MCF10A-HER2 cells were provided courtesy of Emily 
Wang, Ph.D. from the Institute of City of Hope. Culturing MCF10A cells requires 
DMEM/F12 medium from Corning cellgro™. In a 500ml bottle, 25ml of 5% horse serum 
from Sigma® Life Science is added to the medium along with 100µl of 500µg/ml of 
cholera toxin for a final concentration of 100ηg/ml. In addition, 1ml of 5mg/ml insulin 
for a final concentration of 10µg/ml, 63µl of 4mg/ml of hydrocortisone for a final 
concentration of 0.5µg/ml, and 50µl of 200µg/ml of EGF for a final concentration of 
20ηg/ml are added. When detaching cells from cell culture plate, 0.25% of Tripsin 
acquired from Sigma® Life Science. 
 
2.2: Western Blot: 
 Protein extraction was achieved using Triton X. The protein concentration is then 
quantified and normalized to insure equal loading into polyacrylamide gels. 8% 
polyacrylamide gels were used to separate the proteins. Antibodies used were acquired 
from Cell Signaling Technology®. 
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2.3: RNA Extraction: 
MCF10A-Vec and MCF10A-HER2 cells were grown in 6cm ell culture plates to 
90% confluency. TRIzol® was used to extract the RNA by adding 1mL per plate. The 
cells were then scraped off using a scraper and put into a 1.5 ml centrifuge tubes. RNA 
extraction from this point was done using TRIzol® protocol. RNA concentration was 
measured using Epock plate reader (BioTek). 
 
2.4: Poly-adenylation: 
 The RNA that was extracted was poly-adenylated using E.coli poly(A) 
polymerase from New England Biolabs® inc. 2µg of total RNA was added with 1µl of 
poly(A) polymerase. 1µl of 10mM adenosine-5’-triphosphate (ATP) from New England 
Biolabs® inc. was also added. 1µl of recombinant ribonuclease inhibitor named 
RNaseOut™ from Invitrogen was added to the mix. Then, 2µl 10X reaction buffer from 
New England Biolabs® inc. was added. Finally, fill the reaction mix was filled to 20µl 
with RNase-free water from Thermo Scientific. The samples were then incubated at 37°C 
for 1 hour. After the poly-adenylation, 8µl of the poly-adenylated total RNA was mixed 
with 6µl of RNase-free water. Added to the mix was 2µl of 10mM of dNTP from Bioline, 
and 8 µl of 2.5µM of polyT adaptor primer to make a total volume of 24µl. The polyT 
adaptor primer sequence is as follows: 
GCGAGCACAGAATTAATACGACTCACTATAGGTTTTTTTTTTTTVN 
Where N is any nucleotide and V is any nucleotide except thymine (T). The sample was 
then incubated at 65°C for 5 minutes for the primer to anneal. The samples must then 
immediately be chilled on ice. 
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2.5: Quantitative reverse-transcription polymerase chain reaction: 
For the reverse-transcription polymerase chain reaction (RT-PCR), the 24µl 
product from the poly-adenylation step was used and 8µl of 5X first strand buffer from 
Invitrogen was added to it. Additionally, 4µl of 0.1M DTT and 2µl of RNaseOut™ – both 
from Invitrogen – was added to the mix for a total f 38µl. The mix was then brought up 
to 37°C by incubating it for 2 minutes. 2µl of 1X M-MLV reverse transcriptase acquired 
from Invitrogen brings the final volume of the reaction to 40µl. The reaction was then 
incubated for 50 minutes at 37°C. The reaction was terminated by incubating the reaction 
at 70°C for 15 minutes. Finally, the reaction was then diluted by bringing the total 
volume to 400µl (Figure 2.1).  For the quantitative polymerase chain reaction (QPCR), 
10µl of RT² SYBR® Green ROX qPCR Mastermix from Qiagen was added. In addition, 
2µl of cDNA from the previous RT-PCR was added along with 6µl of RNase-free water 
and 1µl of a universal reverse primer with the following sequence: 
GCGAGCACAGAATTAATACGAC 
Finally, 1µl of a forward primer specific to the miRNA in question was added to 
make a total reaction volume of 20µl. The reaction was run in an Applied Biosystem™ 
qPCR machine with the following parameters: Stage 1: 3 minutes hot start at 95°C. Stage 
2: 15 seconds denaturing step at 95°C, followed by 30 seconds annealing step at 60°C, 
and finally, the extension step was held for 35 seconds at 70°C. This stage was repeated 
for 45 cycles. 
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Figure 2.1: Polyadenylation and QRT-PCR assay: 
Polyadenylation occurs after total RNA extraction. Poly A polymerase adds Adenosine to 
the end of miRNAs. Annealing of the oligo-dT adaptor to make a cDNA with a universal 






3.1: Many microRNAs are found to be regulated by overexpression of HER2: 
 For screening purposes, immortalized human breast cell  called MCF10A-Vector 
and its HER2 positive counterpart was used. To confirm whether the HER2 transformed 
cells do produce the HER2 receptor, a western blot was performed for evidence (Figure 
3.1). The MCF10A-HER2 indeed has a higher expression of the phosphorylated HER2 
(p-HER2), which signifies the activation of the HER2 receptor in the cells. The activation 
of HER2 triggers the activation of the downstream signaling pathway. This downstream 
pathway activation is affirmed by the phosphorylation of Akt (p-Akt), a direct 
downstream pathway of HER2, and the phosphorylation of Erk (p-ERK ½), which is 
downstream of the MEK pathway. In addition, the p65 is a subunit of the NFκB and is 
activated by phosphorylation when HER2 is overexpressed (p-p65). To further prove that 
the downstream pathways are dependant on HER2, HER2 was knocked down using 
siRNA. The result from the knock down shows a decrease in expression of HER2, p-Akt, 
and p-ERK ½ but not p-p65. NFκB pathway can be regulated by many different pathways 
other than HER2 which would explain why no change occurs in p-p65. 
MCF10A-Vector and MCF10A-HER2 total RNA was used to screen for potential 
miRNA that are differentially regulated by the overexpression of HER2. 303 miRNA 
primers were created for 303 different miRNA. 
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With the cDNA created from the total RNA and the primers, the 303 miRNA 
expression levels were measured between the MCF10A-Vector and MCF10A-HER2 
using quantitative reverse-transcription polymerase chain reaction (QRT-PCR). The 
results show how many folds the miRNAs have changed from MCF10A-Vector to 
MCF10A-HER2 cells (Figure 3.2a). However, not all results from the QRT-PCR for the 
miRNAs are accurate. Normally, the QRT-PCR product is run in an agarose gel to 
determine if the product of each miRNA primer is correct based on size and number of 
bands visible. The QRT-PCR product is between sixty f ve and seventy bases long 
depending on the size of the mature miRNA being detect d. Therefore, the correct size is 
determined by observing if the product is the correct size, which should be between the 
fifty base pair (bp) and the one hundred bp markers. The miRNAs in figure 3.2b show 
sharp bands at the correct size with the exception of miR-22-3p. Therefore, miRNAs that 
had the wrong size band – higher than roughly one hundred base pairs – or had multiple 
bands were also eliminated. That is because multiple bands indicate a non-accurate 
primer that has amplified a multitude of genes. For example, miR-214-3p (Figure 3.2c) 
shows bands at the wrong size – higher than one hundred base pairs – indicating 
inaccurate primer. Additionally, miRNAs that show no band, like miR-210-5p (Figure 
3.2c), indicate low abundance of those particular miRNAs and are therefore, eliminated. 
It is important to note that ideally we may be able to visualize a difference between the 
band in the MCF10-Vector and MCF10-HER2 band like in miR-219-5p (Figure 3.2b). 
However, the QPCR was run up to forty five cycles and possibly lead to saturation of the 
amplified miRNAs. 
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As a result, the miRNA screening has shrunk to 129 miRNAs that show a single 
band in agarose gels at the correct size (Figure 3.3). Furthermore, expression of cDNA is 
considered unreliable when the expression is detected passed thirty five cycles in QRT-
PCR. In addition, it is known that an up-regulation of only two fold change or higher and 
a down-regulation of negative two fold change or lower are considered a significant 
change in regulation. That is due to the general low abundance of each miRNA in a cell. 
Therefore, miRNAs were eliminated that did not show significant up or down-regulation 
and had detection at thirty five cycles or higher in both MCF10A-Vector and MCF10A-
HER2. Thus, out of these the remaining 129 miRNAs, fourteen miRNAs, were selected 
which are considered the most reliable and strongest candidates (Figure 3.4). 
 
3.2: microRNA in vitro regulation consistent with clinical data: 
miRNA levels from 1,302 breast tumors were acquired f om Dvinge’s group 
where they collected the samples from European tumor banks (Dvinge et al 2013). The 
data was sorted and selected for patients that have died of breast cancer regardless of 
HER2 status. Compared with the data in Figure 3.4, only five miRNAs were found to 
match the differential regulation in that the same iRNAs are either down or up-
regulated in both MCF10A-HER2 and HER2 positive tumor samples (Figure 3.5). miR-
181d and miR-195-5p show down-regulation in MCF10A-HER2 and in HER2 positive 
tumor samples as compared with HER2 negative counterparts (Figure 3.5a, 3.5b, 3.5c). In 
addition, miR-146a-5p shows instead an up-regulation in both the HER2-positive tumor 
sample and MCF10A-HER2 (Figure 3.5a, 3.5d). Moreover, miR-34a and miR-452-5p 
show up-regulation in MCF10A-HER2 and in HER2 positive tumor samples (Figure 3.5a,  
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Figure 3.1: Western blot indicating HER2 overexpression in MCF10A-HER2 
compared with MCF10A-Vector and its downstream pathways: 
 
Western blot analysis indicating the HER2 overexpression in MCF10A-HER2 compared 
to MCF10A-Vec. The overexpression causes the up-regulation of the downstream 
pathways of HER2. MCF10A-HER2 siHER2 is knocked down for HER2 and the 
























Figure 3.2: Identification of differentially expressed miRNAs in HER2 
overexpressing cells using QRT-PCR analysis: 
 
MCF10A-Vector and HER2 were used to screen for differentially regulated miRNAs. a) 
Screening of  303 miRNAs using qRT-PCR and measured according to fold change. b) 
Agarose gel picture depicting the expression of a sample of qRT-PCR products from the 
miRNA screening. c) A second agarose gel picture depicting the expression of a sample 



























Figure 3.3: Selected miRNAs based on qRT-PCR single correct product band size 
and visibility: 
 
From the 303 miRNA in the original screening, miRNAs that did not show a band, did 
not have correct band size, and showed multiple bands were all eliminated. This leaves us 





















Figure 3.4: qRT-PCR of selected candidate miRNAs: 
Differential expression of the selected candidate miRNA in MCF10A-HER2. The 
miRNAs that have negative expression levels are considered down-regulated and have 
lower levels in MCF10A-HER2 as compared with MCF10A-Vector. miRNAs that have 
positive expression levels are considered up-regulated nd have higher levels in 
MCF10A-HER2 as compared with MCF10A-Vector. 
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3.5e, 3.5f). Furthermore, the changes in the HER2-positive tumor samples are statistically 
very significant for all five miRNAs as designated by their P-value. 
After narrowing down the miRNAs in five candidates, these five miRNA 
expression levels were stratified and sorted for each breast cancer subtype. In HER2 
positive patients, miR-34a shows high levels of up-regulation, and, consistently, its 
expression levels are highest in HER2 subtypes in comparison with the other breast 
cancer subtypes (Figure 3.6a). The second up-regulat d miRNA from the five candidates 
is miR-146a-5p. It is observed that between the fivdifferent subtypes, miR-146a-5p 
expression levels are highest in HER2, basal-like, and normal-like breast cancer subtypes 
which could be possible due to their similar morphology (Figure 3.6b). The next miRNA 
is miR-181d, and it is down-regulated in HER2 positive patients. In comparison with the 
subtypes, miR-181d is down-regulated in HER2 subtypes compared to the luminal 
subtypes. However, it shows no significant differenc  between the basal-like and normal-
like breast cancer subtypes (Figure 3.6c). The second d wn-regulated miRNA in HER2 
positive patients is miR-195-5p. In comparison with the normal-like and luminal A breast 
cancer subtypes, the expression level of miR-195-5p is down-regulated significantly 
(Figure 3.6d). However, miR-195-5p expression levels show no difference between 
HER2, luminal b, and basal-like subtypes. Finally, miR-452 is up-regulated in HER2 
positive patients and is therefore also up-regulated in HER2 breast cancer subtype 
compared to luminal A and B (Figure 3.6e). 
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Figure 3.5: Relative expression levels of the five candidate miRNAs in HER2 
positive and negative patient samples: 
 
Expression levels in both MCF10A-HER2 and HER2 positive tumor tissue of five 
candidate miRNAs. a) Shows the expression levels of these miRNAs in MCF10A-HER2 
using QRT-PCR. b) Relative expression level of miR-181d between HER2 negative and 
positive tumor tissues (P-value < 0.0001). c) Relative expression level of miR-195-5p 
between HER2 negative and positive tumor tissues (P-value < 0.0001). d) Relative 
expression levels of miR-146a-5p between HER2 negative nd positive tumor tissues 
with P-value = 0.0003. e) Relative expression levels of miR-452-5p in HER2 negative 
and positive tumor tissues (P-value = 0.0001). f) Relative expression level of miR-34a in 











































































































































































































Figure 3.6: Relative expression of selected candidate miRNAs in breast cancer 
subtypes of tumor samples are differentially regulated in HER2 compared to 
luminal subtypes: 
 
Relative expression of miRNA distributed according to breast cancer subtype. Expression 
levels of each miRNA in HER2 subtype is compared against each other subtypes. a) miR-
34a expression level. b) miR-146a-5p expression levels. c) miR-181d expression levels. 





3.3: miR-34a and miR-452-5p have no correlation to HER2 positive patient survival: 
 Consistent with previous research regarding aggressiv ness of HER2 positive 
cancers, patients whose their tumor samples tested positive for HER2 have shown a 
decrease in survival as compared with HER2 negative tumor samples (Figure 3.7). This 
affirms the importance of understanding and treating HER2 positive cancers. On the 
other hand, when it comes to the miRNAs that are affected by HER2 expression levels, 
miR-34a and miR-452-5p do not show a significant effect on patient survival. In HER2 
negative patients, higher levels of miR-34a increases patient survival percentage (Figure 
3.8c). However, miR-34a does not seem to have any impact on overall patient survival 
(HER2 positive and HER2 negative patients) or even HER2 positive patients. In other 
words, there is no statistically significant percent survival difference between patients 
with higher levels of miR-34a and patients with lower levels of miR-34a (Figure 3.8a, 
3.8b). In addition, miR-452-5p seems to have no impact on breast cancer patient survival.  
There is no significance of percent survival in general patients, HER2 positive patient 
percent survival, or even HER2 negative patient percent survival depending on miR-452-
5p levels (Figure 3.9). However, this does not mean th t these two miRNAs do not have a 
significant role in HER2 overexpressing cancers. This just means that they do not have a 
significant effect on patient survival. 
 
3.4: Patient survival is significantly affected by three miRNAs: 
 Out of the five miRNAs that were differentially regulated in the same pattern in 
both MCF10A-HER2 and HER2 positive tumor samples, only three showed a significant 
impact on patient survivability. The first of these miRNAs is miR-181d. Although miR- 
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Survival of Patients Based on HER2 Status

























Figure 3.7: Kaplan-Meier survival curve based on their HER2 status: 
Blue survival curve shows 1129 patients with HER2 negative tumors. 173 Patients with 
HER2 positive tumors are represented with the red survival curve. The curve is measured 





























HER2 Positive Patient Population

























HER2 Negative Patient Population




























Figure 3.8: Kaplan-Meier survival curve according to miR-34a levels: 
Blue survival curve shows patients with lower than average level of miR-34a. Red curve 
shows patients survival with miR-34a levels that are higher than average. The curve is 
measured in percent of patient survival versus the tim in years. a) General patients’ 
percent survival based on the level of miR-34a (P-value = 0.0641). b) HER2 positive 
patient’s percent survival dependent on miR-34a levels (P-value = 0.6573). c) Survival of 
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Figure 3.9: Kaplan-Meier survival curve based on miR-452-5p levels: 
Impact of miR-452-5p levels on patient survival. Blue survival curve shows patients with 
lower than average level of miR-452-5p. Red curve shows patients’ survival with miR-
34a levels that are higher than average. The curve is measured in percent of patient 
survival versus the time in years. a) General patients’ percent survival dependent on miR-
452-5p levels (P-value = 0.7838). b) HER2 positive patients’ percent survival based on 






181d shows no significant impact on HER2 positive patient survivability (Figure 3.10b), 
it does show statistically significant impact on the survival of the general population of 
patients and in HER2 negative patients’ survivability (Figure 3.10a, 3.10c). With miR-
181d, the higher its levels are, the higher the percentage of patient survival through time 
for both HER2 negative patients and the general patient population. Therefore, this 
indicates that miR-181d does have a significant role or target in the HER2 pathway that 
affects patient survival positively. Therefore, when HER2 is overexpressed, it down-
regulates miR-181d causing it to be unable to functio  as efficiently. It is also important 
to note that the number of patients that express higher than average miR-181d in HER2 
positive patients (Figure 3.10b) is at a lower ratio than the number of patients expressing 
higher than average miR-181d in the general patient population and in the HER2 negative 
patients (Figure 3.10a, 3.10c). In the general patient population and in the HER2 negative 
patient population, the number of patients in lower and higher than average expression of 
miR-181d is nearly equivalent as opposed to the HER2 positive patients. This is due to 
the fact that in HER2 positive patients, the overexp ssion of HER2 causes a significant 
down-regulation of miR-181d to be below average levls where having a higher than 
average expression level is an outlier. 
 The second miRNA that has a significant impact is miR-195-5p. miR-195-5p 
shows no significant statistical impact on the percent survival of HER2 positive patients 
(Figure 3.11b). However, the effect of miR-195-5p is visible when looking at the general 
population of patients and HER2 negative patients (Figure 3.11a, 3.11c). As shown, miR-
195-5p expression levels are directly proportional to patient survivability in the general 
patient population and in HER2 negative patients. Higher levels of miR-195-5p increases 
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patient survival and lower levels of miR-195-5p decrease it. These results are similar to 
that of miR-181d and would produce the same speculation that miR-195-5p targets an 
oncogene. When HER2 is overexpressed, it down-regulates miR-195-5p, causing it to be 
unable to efficiently inhibit the translation of the oncogene’s mRNA. Likewise, it is also 
important to note the sample numbers for each population of patients. Unlike miR-181d, 
miR-195-5p’s general patient population is not distributed in equal ratios between the 
above and below average miR-195-5p expression (Figure 3.11a). The population of 
HER2 negative patients is also not distributed evenly between miR-195-5p that is above 
or below average expression levels (Figure 3.11c). However, when looking at the 
population distribution in HER2 positive patients, we are able to notice that the number 
of patients that are expressing lower than average miR-195-5p is more than the number of 
patients expressing above average miR-195-5p (Figure 3.11b). This trend also follows 
that of miR-181d in HER2 positive patients where th number of patients expressing 
lower than average miR-181d is more than the patients xpressing above average miR-
181d levels (Figure 3.10b). Like miR-181d, the reason for this distribution of patients in 
HER2 positive patients is because HER2 overexpression causes a down-regulation of 
miR-195-5p in most patients that an above average expression level is an outlier. 
Finally, the third miRNA that is significantly impacting patient survivability is 
miR-146a-5p. HER2 positive patients show no significant impact due to the levels of 
miR-146a-5p (Figure 3.12b). However, as with the prvious two miRNAs, the impact of 
miR-146a-5p on survivability is most evident in thegeneral patient population and HER2 
negative patients (Figure 3.12a, 3.12c). For both the general patient population and HER2 
negative patients, the higher the levels of miR-146a-5p, the lower the patients’ percent 
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survival, making miR-146a-5p inversely proportional to patient survivability. Opposite 
from what is observed in miR-181d and miR-195-5p, the number of patients expressing 
above average miR-146a-5p is larger than the number of patients expressing lower than 
average miR-146a-5p in HER2 positive patients (Figure 3.12b). That is due to the 
overexpression of HER2 where it up-regulates miR-146a-5p in the majority of patients 
and that patients that have lower than average miR-146a-5p expression are outliers. 
However, the patient distribution between above and below average miR-146a-5p 
expression in the general patient population shows a shift towards the lower than average 
expression and HER2 negative population shows an eve distribution. 
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Figure 3.10: Kaplan-Meier survival curve based on miR-181d levels: 
miR-181d’s levels’ effect on patient survival. Blue survival curve shows patients with 
lower than average level of miR-181d. Red curve shows patients’ survival with miR-34a 
levels that are higher than average. The curve is measured in percent of patient survival 
versus the time in years. a) General patients’ percent survival based on the level of miR-
181d (P-value = 0.0034). b) Survival of patients with HER2 positive tumors based on 
miR-181d levels (P-value = 0.2188). c) HER2 negative patient’s percent survival 
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Figure 3.11: Kaplan-Meier survival curve according to miR-195-5p levels: 
miR-195-5p’s levels’ effect on patient survival. Blue survival curve shows patients with 
lower than average level of miR-195-5p. Red curve shows patients’ survival with miR-
195-5p levels that are higher than average. The curve is measured in percent of patient 
survival versus the time in years. a) General patients’ percent survival based on the level 
of miR-195-5p (P-value < 0.0001). b) Survival of patients with HER2 positive tumors 
based on miR-195-5p levels (P-value = 0.8362). c) HER2 negative patients’ percent 
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Figure 3.12: Kaplan-Meier survival curve according to miR-146a-5p levels: 
miR-146a-5p’s levels’ effect on patient survival. Bue survival curve shows patients with 
lower than average level of miR-146a-5p. Red curve shows patients’ survival with miR-
146a-5p levels that are higher than average. The curve is measured in percent of patient 
survival versus the time in years. a) General patients’ percent survival based on the level 
of miR-146a-5p (P-value = 0.0317). b) Survival of patients with HER2 positive tumors 
based on miR-146a-5p levels (P-value = 0.3398). c) HER2 negative patients’ percent 








 Since their discovery in 1993, miRNAs have been extensively studied for over 
two decades with many exciting results (Lee et al 1993). However, there are over a 
thousand human miRNAs that have so far been discovered and only a small portion has 
been studied. Furthermore, within the small portion of miRNAs that have been studied, 
there remains many areas of each single miRNA to be studied whether in regulation of 
human physiology or the impact of these miRNAs on any type of cancer and its related 
hallmarks. Typically, the most recently discovered miRNAs are the most extensively 
studied due to their high abundance in cells. This high abundance is the reason for these 
miRNAs’ early detection as compared to miRNAs that are detected much later in the 
years. Moreover, miRNAs in HER2 positive breast cancers have not been intensively 
studied leaving much information still unknown about HER2 positive breast cancer and 
its interaction with miRNAs. 
 Starting off, it is important to note that our data shows the significance of how 
overexpression of HER2 effects patient survival. In co firmation with many previous 
research on HER2, it is shown in this population sample that overexpression of HER2 
does indeed decrease patient survival with a very high statistical significance. MCF10A 
cells are known as immortalized breast epithelial cells that can serve as non-cancerous 
control cells. By overexpressing HER2 in MCF10A, the effect of overexpression can be 
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studied as this overexpression is the only significant variable. As part of the screening, 
many miRNAs are observed to be differentially regulated based on the HER2 expression 
levels in MCF10A cells. However, not all miRNAs’ differential expression based on 
HER2 translates into cancerous cells or tumor samples. Therefore, only a small number 
of miRNA – specifically five – maintain their trend of expression. In other words, 
miRNAs that are up-regulated in MCF10A-HER2, such as miR-146a-5p, miR-34a, and 
miR-452-5p, are indeed up-regulated in HER2 positive tumor samples as compared with 
HER2 negative tumor samples; and in addition, miRNAs that are down-regulated in 
MCF10A-HER2 such as miR-181d and miR-195-5p, are in fact down-regulated in HER2 
positive tumor samples as compared with HER2 negative tumor samples. Thereby, the 
miRNAs from the original screening are narrowed down from around 303 miRNAs to 
only five potential targets. 
 To further confirm the differential regulation of these miRNA based on HER2, we 
can see in figure 3.4 that these miRNA are expressed in the same profile in HER2 breast 
cancer subtype compared with luminal A and luminal B subtypes. It is worth noting that 
miR-34a is the miRNA that shows the most significant difference in HER2 subtypes 
compared to all other breast cancer subtypes. This indicates that miR-34a is possibly the 
miRNA that is most affected by HER2 expression as the major regulator. Another 
interesting miRNA when speaking about the breast cancer subtypes is miR-146a-5p. In 
the HER2 subtypes, miR-146a-5p is significantly higher when compared with the luminal 
subtypes as is expected. In addition, the luminal A nd B subtypes show a surprisingly 
very low expression level. This could be possibly due to the fact that the luminal subtypes 
are ER positive. It has been shown that estrogen expression down-regulates the activation 
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of NFκB by enhancing IκB levels (Xing et al 2012); and that with NFκB is positively 
correlated with the expression of miR-146a-5p (Taganov et al 2006). However, the basal-
like breast cancer subtype shows an even higher expression level than that of the HER2 
subtypes. This may be due to the fact that some basal-like tumors, though they are triple-
negative, are HER2 enriched (Perou 2011). With this HER2 enrichment – coupled with 
the absence of ER – miR-146a-5p expression is further amplified. The last three miRNAs 
are miR-195-5p, 181d, and 452-5p, and they show their expected expression profile when 
compared with the luminal subtypes. However, when compared with the basal-like and 
normal-like subtypes, due to the fact that basal-like is enriched with HER2 and the 
morphological resemblance and aggressiveness of normal-like, the HER2 subtype 
miRNA expression levels show no difference. The major possibility is, due to the 
similarity between these three subtypes, cross regulation from other pathways can affect 
the expression of these three miRNA resulting in no significant difference. 
 However, these five miRNAs are nothing more than potential targets which need 
further testing to validate as legitimate factors in patient survival. As such, when 
searching through the data from the Dvinge group in regards to patient survivability, two 
miRNAs begin to show their insignificance to patien survival between HER2 positive 
and HER2 negative patients. The first of those miRNAs is miR-452-5p. Although miR-
452-5p shows up-regulation in MCF10A-HER2 and in HER2 positive tumor samples, its 
effect on the patients from which the tumor samples w re taken from is statistically 
insignificant. This insignificance is evident in all of miR-452-5p on patient survival, 
including general patient population survival based on miR-452-5p expression levels. 
The second of those miRNAs is miR-34a. Even though miR-34a generally follows the 
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same trend as miR-452-5p, it does have a statistically significant effect on HER2 negative 
patient survival. However, miR-34a does not show any significant effect on patient 
survival in both the general patient population ando  HER2 positive patient survival. 
This does not mean that its effect on the HER2 negative patient survival can be ignored; 
it can simply be that it is not the major player of patient survival but a co-contributor. 
Finally, while these two miRNAs do not have a major effect on patient survival, they can 
have other effects, such as tumor initiation or tumor progression. 
The next three miRNAs from the original five are observed to have a very 
statistically significant impact on patient survival. The first of these three miRNAs is 
miR-146a-5p. The fact that there have been many reports of miR-146a-5p being up-
regulated in many cancers, including breast cancer, helps support the fact that miR-146a-
5p can have a significant impact on patient survival in HER2 positive breast cancer 
patients (Labbaye & Testa 2012). In this study, miR-146a-5p is indeed up-regulated in 
HER2 positive breast cancer patients and in MCF10A-HER2. This indicates that miR-
146a-5p is up-regulated directly or indirectly by HER2 overexpression. 
Furthermore, it is observed that the up-regulation of miR-146a-5p decreases 
patient survival in both HER2 negative patients andin the general patient population. 
This means that miR-146a-5p is an oncomir should targe  a tumor suppressor gene that 
would control the tumor aggressiveness, for example. However, miR-146a-5p does not 
cause a significant change in HER2 positive patients. The reason for this is because in 
HER2 positive patients generally observe above average miR-146a-5p levels due to the 
overexpression of HER2. Therefore, any increase in up-regulation is not going to have a 
higher decrease in patient survival because miR-146a-5p is already above the threshold. 
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The second miRNA that has considerable impact on patient survival is miR-195-
5p. Like miR-146a-5p, miR-195-5p has been extensively studied, especially in breast 
cancer, as it was found to be down-regulated (Ouyang et al 2014). It has also been 
suggested as a possible diagnostic target for breast cancer (Luo et al 2014). Thus, miR-
195-5p is solidified as an important target in breast cancer and supports the data in this 
study. In accordance with previous research, miR-195-5p is down-regulated in MCF10A-
HER2 and also in HER2 positive. These results thus supports the idea that miR-195-5p is 
regulated by the level of HER2 expression. However, it is unknown how this regulation 
occurs whether it is direct or indirect. 
Moreover, miR-195-5p is shown to be directly proportional to the percent survival 
of the general patient population and the HER2 negative patients – the same two samples 
as miR-146a-5p. This means that the lower the levels of miR-195-5p, the lower the 
chance for patient survival. This further means that miR-195-5p is a tumor suppressor 
miRNA that targets an oncogene that would normally have an adverse effect on the 
patient. Like miR-146a-5p, miR-195-5p shows no signif cant effect on patient percent 
survival in HER2 positive patients. The reason is also similar to miR-146a-5p in that 
miR-195-5p is down-regulated below the threshold with the overexpression of HER2 in 
HER2 positive patients; and that when the levels are already below the threshold, any 
change in the levels would not have any more impact than what has already been 
observed. 
The final and third miRNA that has a significant effect on patient survivability is 
miR-181d. Unlike the previous two miRNAs, miR-181d has not been extensively studied. 
The amount of information and connection between miR-181d and cancer is scarce, and 
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it is even more so in HER2 positive breast cancers. However, it has been observed that 
the miR-181 family (miR-181a, miR-181b, miR-181c, and miR-181d), more precisely 
miR-181c, is activated by HER2 expression (Lowery et al 2009). Even though miR-181c 
is possibly co-expressed or repressed with miR-181d, there has not been much research 
done regarding this co-expression or repression. Therefore, it is plausible that miR-181d 
is down-regulated with the overexpression of HER2 in both MCF10A-HER2 and HER2 
positive patients. 
Like miR-195-5p, miR-181d is shown to be directly pro ortional to patient 
survival in both HER2 negative patients and the general patient population. These two 
populations are again the same two populations affected by the two miRNAs that have 
been previously discussed. Along the same previous l ne , the higher levels of miR-181d 
the higher the chances for patient survivability. Therefore, miR-181d can be classified as 
a tumor suppressor miRNA targeting an oncogene. Similar to the two previously 
discussed miRNA, miR-181d shows no significant effect on patient survival in HER2 
positive patients. The explanation for this phenomenon is the same with miR-195-5p in 
that miR-181d is down-regulated below the threshold with the overexpression of HER2 
in HER2 positive patients; and that when the levels are already below the threshold, any 
change in the levels would not have any more impact than what has already been 
observed. 
Finally it is important to understand how all these miRNA tie in together in the 
HER2 pathway and how they affect the behavior of HER2 positive breast cancer. From 
previous research, HER2 has been discovered to directly activate the NF-κB independent 
of PI3K/Akt protein by activating IκB kinase α (IKKα). Activation of IKKα causes the 
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phosphorylation of IκB, which stops its inhibitory activity on NF-κB. Interestingly, 
induction of miR-146a-5p is positively dependent on the activation of NF-κB (Taganov et 
al 2006). Furthermore, ERBB receptor feedback inhibitor 1 (ERRFI1) which can target 
and inhibit HER2 (Segatto et al 2011), is suggested to be a potential target of miR-146a-
5p (Garcia et al 2011). Although this potential target needs experimental confirmation, if 
it is true, then this interaction can explain why HER2 positive cells can keep 
overexpressing HER2 without hindrance; and that would be due to miR-146a-5p 
inhibiting ERRFI1. However, the complex pathway does involve at least one more 
component and that is miR-195-5p. Research has shown that miR-195-5p down-regulates 
the NF-κB pathway by targeting and thereby inhibiting IKKα (Ding et al 2013). 
Therefore, it would down-regulate the expression of miR-146a-5p. Unfortunately, miR-
195-5p is down-regulated and has no effect on the expression of miR-146a-5p in HER2 
overexpressing tumors. However, there are two unknown factors in this pathway we 
propose (Figure 4.1). These two factors are how both miR-195-5p and miR-181d are 
regulated by HER2, whether it is directly or indirectly by HER2’s many down-stream 
proteins. 
In conclusion, with better understanding of the HER2 pathway, we are better able 
to treat HER2 positive tumors. With the understanding that miR-146a-5p, miR-181d, and 
miR-195-5p are differentially regulated by HER2, it is possible to use these miRNAs as 
potential targets for drugs designed to inhibit miR-146a-5p for example. It is also 
possible to hinder tumor progression by inducing the production of miR-195-5p or miR-
181d. Finally it is possible to use any of these miRNA as possible biological markers for 
tumors that can be detected early. 
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Figure 4.1: Proposed regulation model of HER2 pathway by the selected miRNAs: 
 
HER2 pathway involving miR-195-5p, miR-146a-5p, and miR-181d. Inhibition of miR-
195-5p by HER2 directly or indirectly is unknown. Ihibition of miR-181d directly or 
indirectly is unknown. miR-195-5p targets IKKα which eventually effects miR-146a-5p. 
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